Skip to main content
THERACRYF PLC logo

THERACRYF PLC — Investor Relations & Filings

Ticker · TCF ISIN · GB00BSVYN304 LEI · 213800NO3E6TSTQO8K20 IL Professional, scientific and technical activities
Open in API
Filings indexed 362 across all filing types
Latest filing 2016-06-02 Report Publication Anno…
Country GB United Kingdom
Listing IL TCF

About THERACRYF PLC

https://theracryf.com/

TheraCryf PLC is a clinical-stage therapeutics company focused on developing a new generation of innovative medicines for behavioural brain disorders and oncology. The company's research and development efforts are centered on sulforaphane-based compounds. Its primary therapeutic focus is on conditions such as opioid and alcohol abuse, binge eating disorder, anxiety, and fatigue. TheraCryf's business strategy is to generate compelling clinical data for its drug candidates with the goal of partnering its programs with larger pharmaceutical companies for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Posting of Annual Report and AGM Notice
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) from Evgen Pharma PLC stating that their Annual Report and Accounts and the notice of the Annual General Meeting have been posted to shareholders and are available on their website. According to the 'Menu vs Meal' rule, this is an announcement of the publication of reports rather than the reports themselves, making it a Report Publication Announcement (RPA).
2016-06-02 English
Final Results
Annual Report Classification · 95% confidence The document is titled 'Final Results for the year ended 31 March 2016' and contains detailed financial performance, operational reviews, and strategic outlooks for Evgen Pharma plc. It provides substantive financial data (loss figures, cash positions) and management analysis. While it is released via an RNS (Regulatory News Service) feed, the content is a comprehensive annual financial report rather than a mere announcement of one. Therefore, it is classified as an Annual Report (10-K equivalent for this jurisdiction). FY 2016
2016-05-31 English
Notification of Preliminary Results
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) from Evgen Pharma PLC stating that they will announce their preliminary results on a future date (31 May 2016). It does not contain the actual financial results, but rather serves as a notification of the upcoming report publication. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2016-05-09 English
First Patient Dosed in Phase II Trial
Regulatory Filings Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from the London Stock Exchange regarding Evgen Pharma PLC. It details the commencement of a Phase II clinical trial for a drug candidate (SFX-01). Since this is a general corporate announcement regarding business operations and clinical trial milestones that does not fit into specific categories like financial reports, dividends, or M&A, it falls under the 'Regulatory Filings' (RNS) category.
2016-05-03 English
Approval of Phase II Clinical Trial in SAH
Regulatory Filings Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from the London Stock Exchange regarding Evgen Pharma PLC. It details the approval of a Phase II clinical trial for a drug candidate (SFX-01). Since this is a general corporate announcement regarding business operations and regulatory milestones that does not fit into specific categories like financial reports, dividends, or director dealings, it is classified as a Regulatory Filing (RNS).
2016-03-02 English
Correction: Director Share Purchases
Director's Dealing Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from Evgen Pharma PLC regarding a correction to a previous disclosure about director share purchases. It explicitly details the number of shares purchased by specific directors and their resulting holdings. This falls under the category of 'Director's Dealing' (DIRS), as it reports personal share transactions by company directors.
2016-01-19 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.